Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Multiple Myeloma 1Lung Neoplasms 1Ewing's Sarcoma Family of Tumors 1Colorectal Neoplasms 1Carcinoma, Adenosquamous 1Carcinoma 1Advanced Non-Hematologic Malignancies 1Advanced Cancer 1

Interventions

Paclitaxel 2Carboplatin 2fludarabine phosphate 1fludarabine 1figitumumab 1aldesleukin 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Interleukin-2 1Cyclophosphamide 1Chemoradiotherapy 1Cetuximab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Adenosquamous × figitumumab × Clear all
NCT00596830 2014-01-13

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Pfizer

Phase 3 Terminated
681 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡